News | Radiation Therapy | September 07, 2016

ASTRO Announces Featured Clinical Trials and Research for 2016 Annual Meeting

Press program will highlight innovations in cancer care from 15 leading studies in five news briefings held live on-site and via webcast

ASTRO 2016 annual meeting, clinical trials and research, press program, radiation therapy

September 7, 2016 — The American Society for Radiation Oncology (ASTRO) announced the press program for its 58th Annual Meeting, Sept. 25-28 in Boston. The program includes multiple reports from phase III clinical trials, researchers from leading institutions in the United States and abroad, and examinations of a range of cancer types and patient populations. Researchers will share their findings in a series of briefings held on-site at the Boston Convention & Exhibition Center and webcast to registered press.

The news briefing schedule is as follows:

Meeting Overview & Report on ASTRO Initiatives

  • Sunday, Sept. 25, 2:45 - 3:15 p.m. ET
  • Features David C. Beyer, M.D., FASTRO, current president and incoming chair of ASTRO

Refining Treatment Decisions

  • Monday, Sept. 26, 8:00 - 9:00 a.m. ET
  • Features studies evaluating conventional versus accelerated treatment approaches for brain metastases, lung cancer and prostate cancer

Expanding Access to Care

  • Monday, Sept. 26, 10:30 - 11:30 a.m. ET
  • Features studies on expanding care to overlooked or growing patient populations, including elderly patients, African Americans, developing countries and veterans

Advances in Prostate Cancer Care

  • Tuesday, Sept. 27, 8:00 - 9:00 a.m. ET
  • Features large trials and multi-institution studies examining treatment advances in brachytherapy, teletherapy and biomarker subtyping for prostate cancer

Innovations in RT Delivery

  • Tuesday, Sept. 27, 1:30 p.m. - 2:30 p.m. ET
  • Features reports of how new approaches to radiation therapy delivery impact disease control and quality of life for gynecologic, breast and pediatric brain cancers

 

The 2016 ASTRO Annual Meeting is expected to attract more than 11,000 attendees from across the globe, including oncologists from all disciplines and members of the entire radiation oncology team. The meeting will feature abstracts, scientific and educational presentations on radiation oncology clinical trials and research, and keynote addresses from former U.S. Secretary of Health and Human Services Kathleen Sebelius, the current chair and CEO of the Massachusetts General Physicians Organization and a top safety executive from Delta Air Lines.

Led by Beyer, the 2016 meeting is organized around the theme, “Enhancing Value, Improving Outcomes,” echoing growing calls from policy makers, physicians and patients for value-based health care. Concurrent with the scientific and educational program, more than 200 exhibitors will demonstrate the latest cutting-edge technology and medical device innovations for radiation oncology.

For more information: www.astro.org

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

News | Radiation Therapy | April 07, 2020
April 7, 2020 — An intern...
Eclipse v16 has received CE mark and is 510(k) pending
News | Proton Therapy | April 06, 2020
April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technolo
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 New studies use SIRD model to forecast COVID-19 spread; examine patient CT scans to correlate clinical features with mortality

Fig 1. A sample scoring on CT images of a 63-year-old woman from mortality group demonstrated a total score of 63. It was calculated as: for upper zone (A), 3 (consolidation) × 3 (50–75% distribution) × 2 (both right and left lungs) + 2 (ground glass opacity) ×1 (< 25% distribution) × 2 (both right and left lungs); for middle zone (B), 3 (consolidation) × 2 (25–50% distribution) × 2 (both right and left lungs) + 2 (ground glass opacity) × 2 (25–50% distribution) × 2 (both right and left lungs); for lower zone (C), 3 (consolidation) × (2 (25–50% distribution of the right lung) + 3 (50–75% distribution of the left lung)) + 2 (ground glass opacity) × (2 (25–50% distribution of the right lung) + 1 (< 25% distribution of the left lung)) Yuan et al, 2020 (CC BY 4.0)

News | Coronavirus (COVID-19) | April 01, 2020
April 1, 2020 — A new study, ...
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals 

News | Radiation Oncology | March 16, 2020
March 16, 2020 — The Ann...